Pulse Biosciences (NASDAQ:PLSE) Upgraded at StockNews.com

StockNews.com upgraded shares of Pulse Biosciences (NASDAQ:PLSE) to a sell rating in a report released on Tuesday morning.

Pulse Biosciences Stock Down 1.3 %

NASDAQ:PLSE traded down $0.22 during trading hours on Tuesday, hitting $16.89. 17,907 shares of the company were exchanged, compared to its average volume of 203,017. The company’s 50 day moving average price is $17.36 and its 200-day moving average price is $14.93. Pulse Biosciences has a 52-week low of $5.97 and a 52-week high of $22.69.

Pulse Biosciences (NASDAQ:PLSE) last issued its quarterly earnings results on Wednesday, October 30th. The company reported ($0.21) EPS for the quarter. During the same period in the prior year, the business earned ($0.19) earnings per share.

Institutional Investors Weigh In On Pulse Biosciences

Institutional investors have recently modified their holdings of the business. BNP Paribas Financial Markets boosted its position in Pulse Biosciences by 63.6% during the first quarter. BNP Paribas Financial Markets now owns 7,597 shares of the company’s stock worth $66,000 after purchasing an additional 2,952 shares in the last quarter. Inspire Investing LLC lifted its position in shares of Pulse Biosciences by 32.1% during the 1st quarter. Inspire Investing LLC now owns 41,358 shares of the company’s stock valued at $360,000 after buying an additional 10,039 shares in the last quarter. Vanguard Group Inc. grew its stake in Pulse Biosciences by 28.8% in the 1st quarter. Vanguard Group Inc. now owns 847,212 shares of the company’s stock valued at $7,379,000 after acquiring an additional 189,227 shares during the period. Price T Rowe Associates Inc. MD purchased a new stake in Pulse Biosciences in the 1st quarter worth $88,000. Finally, Cetera Advisors LLC acquired a new position in Pulse Biosciences during the first quarter worth $109,000. 76.95% of the stock is currently owned by institutional investors and hedge funds.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.